SynthesisFrontiers in medicine2026
Comparative efficacy of different durations and dosages of vonoprazan and amoxicillin dual therapy: a network meta-analysis of randomized controlled trials.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The combination of vonoprazan and amoxicillin (VA) has been shown to be effective in eradicating Methods: A systematic literature search of PubMed, Embase, and China National Knowledge Infrastructure was performed to identify randomized controlled trials (RCTs) comparing different durations of VA dual therapy or comparing this dual therapy with bismuth-containing quadruple therapy (BQT). All trials were conducted in China. A Bayesian network meta-analysis was used to evaluate the eradication rates and incidence of adverse events across different treatment regimens. Results: Thirty-eight randomized controlled trials were ultimately included in the analysis. Network meta-analysis revealed that both the 14- and 10-day VA regimens achieved higher eradication rates compared with BQT, with odds ratios (OR) of 1.7 [ Conclusion: The 14-day low-dose VA dual regimen offered a favorable balance between efficacy and safety, suggesting that it may be a promising option for Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261284331, identifier: CRD420261284331.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.